{
    "organizations": [],
    "uuid": "8ea4fc8f5ad7d83434de1475419daf94171f7875",
    "author": "",
    "url": "https://www.reuters.com/article/brief-avid-bioservices-oncologie-enter-i/brief-avid-bioservices-oncologie-enter-into-asset-assignment-purchase-agreement-for-avids-ps-targeting-program-including-bavituximab-idUSFWN1Q211S",
    "ord_in_thread": 0,
    "title": "BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 16 PM / Updated 6 minutes ago BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Avid Bioservices Inc: \n* AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVID’S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB \n* AVID BIOSERVICES INC - ‍AVID WILL RECEIVE $8 MILLION IN UPFRONT PAYMENTS FROM ONCOLOGIE PAID OVER A PERIOD OF SIX MONTHS FROM EXECUTION DATE OF AGREEMENT​ \n* AVID BIOSERVICES INC - ‍AVID WILL BE ELIGIBLE TO RECEIVE UP TO $95 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIALIZATION MILESTONES​ \n* AVID BIOSERVICES - ‍ONCOLOGIE TO BE RESPONSIBLE FOR FUTURE RESEARCH, DEVELOPMENT & COMMERCIALIZATION OF BAVITUXIMAB, RELATED INTELLECTUAL PROPERTY COSTS​ \n* AVID BIOSERVICES INC - ‍ONCOLOGIE WILL ENTER INTO DEAL WITH AVID FOR FUTURE CONTRACT DEVELOPMENT AND MANUFACTURING ACTIVITIES IN SUPPORT OF BAVITUXIMAB​ Source text for Eikon: Further company coverage:",
    "published": "2018-02-12T15:14:00.000+02:00",
    "crawled": "2018-02-12T15:35:51.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "bioservices",
        "oncologie",
        "enter",
        "asset",
        "assignment",
        "purchase",
        "agreement",
        "avid",
        "program",
        "including",
        "bavituximab",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "avid",
        "bioservices",
        "inc",
        "avid",
        "bioservices",
        "oncologie",
        "enter",
        "asset",
        "assignment",
        "purchase",
        "agreement",
        "avid",
        "program",
        "including",
        "bavituximab",
        "avid",
        "bioservices",
        "inc",
        "receive",
        "million",
        "upfront",
        "payment",
        "oncologie",
        "paid",
        "period",
        "six",
        "month",
        "execution",
        "date",
        "avid",
        "bioservices",
        "inc",
        "eligible",
        "receive",
        "million",
        "development",
        "regulatory",
        "commercialization",
        "avid",
        "bioservices",
        "responsible",
        "future",
        "research",
        "development",
        "commercialization",
        "bavituximab",
        "related",
        "intellectual",
        "property",
        "avid",
        "bioservices",
        "inc",
        "enter",
        "deal",
        "avid",
        "future",
        "contract",
        "development",
        "manufacturing",
        "activity",
        "support",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}